Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Rank in Stocks #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Share Price
$0.5225
Last synced: 2026-08-14
Market Cap
$4.32M
Change (1 day)
-1.60%
Change (1 year)
-63.72%
Country
IL
Trade Galmed Pharmaceuticals Ltd. (GLMD)

Category

Stock price history for Galmed Pharmaceuticals Ltd. (GLMD)
Highest end of day price: $0.57 on 2026-08-01

Lowest end of day price: $2.34K on 2014-03-01
Stock price history of Galmed Pharmaceuticals Ltd. from 2014 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -9.47%
2025 -67.60%
2024 -35.91%
2023 -93.04%
2022 -82.49%
2021 -40.56%
2020 -40.27%
2019 -24.43%
2018 -7.34%
2017 144.28%
2016 -57.96%
2015 53.42%
2014 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE